Heart failure & cardiomyopathies
Tricuspid Regurgitation and Clinical Outcomes in Heart Failure With Reduced Ejection Fraction
Authors' conclusion
In symptomatic patients with HFrEF, baseline moderate/severe TR was independently associated with cardiovascular death or HF events driven predominantly by HF events. The beneficial treatment effect of omecamtiv mecarbil on the primary outcome was not modified by TR.
Study context
- Population
- Patients with symptomatic heart failure with reduced ejection fraction (HFrEF) in the GALACTIC-HF trial (omecamtiv mecarbil vs placebo)8,180 with baseline tricuspid regurgitation (TR) data
- Participants
- 8,232 patients
- Comparison
- Moderate/severe or mild TR vs no TR
- Nonen = 6,476reference
- Mildn = 919
- Moderate/severen = 785
- Primary endpoint
- First HF event or CV death
Methodological detailsdouble-blind, placebo-controlled
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
Adjusted hazard ratio (95% CI)P value
Moderate/severevs None
1.12(1.01–1.26)
P = 0.046Moderate/severevs No/mild TR
1.14(1.02–1.27)
P = 0.025Further findings
Association of moderate/severe TR with outcomes, by subgroup
- More pronounced in outpatients and in those with worse renal function, higher LVEF, and lower NT-proBNP and bilirubin
Treatment effect of omecamtiv mecarbil vs placebo, by TR
- Beneficial treatment effect not modified by TR
Original publication
Tricuspid Regurgitation and Clinical Outcomes in Heart Failure With Reduced Ejection Fraction. JACC Heart Fail. Published 31 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →